CD8A and colorectal carcinoma: Our results suggest that integrating these two automated objective markers, CD8+ T-lymphocyte fraction and stroma fraction, with widely accepted clinicopathological high-risk factors, can help to refine prognostic information for stage II/ΙΙΙ CRC.